Abstract: The disclosure relates to a syringe support for supporting an axial position of a syringe relative to a housing of an autoinjector. The syringe support comprises a projecting portion, which projects from the syringe support in a distal direction and a flexible portion which axially adjoins the projecting portion. The flexible portion is adapted to axially bias the syringe in the distal direction within the housing. The disclosure further relates to an autoinjector.

Abstract: A drug delivery device is proposed which comprises: a housing defining an interior; a reservoir which is adapted to contain a drug or contains a drug, the reservoir being retained in the interior; and a closure part which is secured relative to the housing and has to be disconnected from the housing to get access to the reservoir within the interior, wherein the closure part is secured relative to the housing by a connection, wherein the connection comprises a welded connection, and wherein the welded connection is formed between two join partners, i.e. a first join partner and a second join partner. Further, a method for manufacturing a drug delivery device is disclosed as is a use associated with drug delivery devices.

Abstract: A communications server for validating a token on a user device, the communications server comprising a memory storing: a list of locations; a first unique code associated with each location; a second unique code associated with each location; a user device product threshold; and a number of previously validated tokens for the user device, wherein the communications server is configured to: receive a first communication from the user device specifying the first unique code associated with a particular location; compare the number of previously validated tokens for the user device against the user device product threshold; when the number of previously validated tokens for the user device does not exceed the user device product threshold, send a reservation message to the user device, the reservation message causing the token on the user device to be reserved for use at the particular location; receive a second communication from the user device, the second communication specifying the second unique code assoc

Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.

Abstract: Described is a medicament container carrier adapted to hold a first medicament container having a first predetermined size and capable of containing more than a first volume of a medicament. The container carrier comprises a body, and an adapter coupled to the body. The adapter is adapted to hold a second medicament container having a second predetermined size different from the first predetermined size and capable of containing no more than the first volume of the medicament.

Abstract: The present disclosure provides antibodies and antigen-binding fragments that target transferrin receptor. Also provided is the use of these antibodies and antigen-binding fragments as carriers to deliver therapeutic molecules across the blood-brain barrier.

Abstract: Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.

Abstract: In one aspect, this disclosure describes methods of treating or preventing RSV infection in a patient in need thereof. The methods include dosing regiments for administering a composition including a fixed dose of an anti-RSV monoclonal antibody or an antigen binding fragment thereof. In another aspect, this disclosure describes pharmaceutical compositions for the treatment or prevention of RSV infection. In yet another aspect, this disclosure describes a pharmaceutical unit dose including nirsevimab.

Abstract: An apparatus is disclosed, comprising a detector unit comprising a detector configured to detect an actuation action performable via the detector unit to an actuation button of a medical device to cause the medical device to eject at least a portion of a medicament comprised in the medical device. The detector is configured to detect the actuation action based on a detection of a force and/or a touch applied to the detector unit as part of the actuation action. The apparatus further comprises an electric unit connected to the detector and configured to store and/or provide information related to the detected actuation action. Furthermore, an according method and a computer program for controlling this method are disclosed.

Abstract: The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: A method and system for detecting a limit of use of a medical device is disclosed. The method includes starting a timer of a medical device when said medical device is used for the first time, detecting the limit of use of the medical device and indicating the limit of use of the medical device. The limit of use is reached when at least one of a first criterion and a second criterion is met, wherein the first criterion is that the timer reaches or exceeds a time limit and wherein the second criterion is that at least one operation of a drive train of said medical device reaches or exceeds a limit.

Abstract: Herein are provided a combination of everolimus and of amcenestrant or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

Abstract: Herein are provided a combination of ribociclib, or a pharmaceutically acceptable salt thereof, such as ribociclib succinate, and amcenestrant, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

Abstract: An autoinjector includes a case, a needle shroud telescopically coupled to the case, a carrier slidably arranged in the case, a collar rotatably and slidably disposed in the case and coupled to the needle shroud and the carrier, and a trigger button operably coupled to the carrier. The case includes a rib. The needle shroud is movable between a first extended position, a retracted position, and a locked second extended position. The carrier is adapted to hold a medicament container and movable from a first axial position to a second axial position relative to the case. The carrier abuts the rib in the first axial position and the needle shroud is in the first extended position and disengages the rib when the needle shroud is in the retracted position and the trigger button is pressed to advance the carrier to the second axial position.

Abstract: The present disclosure relates to a touch sensitive label for an injection device, the label comprising: a flexible substrate configured for attachment to a housing of the injection device, an electronic display located on the substrate and configured to visually display at least one indication, a touch sensitive area located on the substrate and electrically connectable to the electronic display, and a processor connected to the electronic display and configured to modify the visual appearance of the at least one indication in response to a user touching or depressing the touch sensitive area.

Abstract: Embodiments of the present disclosure are directed to conserving energy of an injection device that includes an energy source, an electronic component configured to be electrically decoupled from the energy source, a priming component configured to generate a trigger, and a mechanism attached to the priming component and configured to perform operations comprising in response to receiving the trigger, electrically coupling the energy source to the electronic component.

Abstract: The present disclosure relates to a drug delivery device having a case adapted to retain a medicament container, a plunger disposed within the case and slidable from a proximal position into a distal position for delivering a medicament from the medicament container, and at least one feedback mechanism that is in operative connection with the plunger. The feedback mechanism includes a collar, a needle shroud, and a control spring biasing the needle shroud in a distal direction relative to the collar. The collar is operatively coupled to the case in an axial direction and prevented from axially decoupling from the case by the plunger when in the proximal position. The plunger, during movement from the proximal position towards the distal position, allows axial decoupling of the collar from the case driven by the control spring until the collar's movement is halted, which creates an audible and/or tactile feedback.

Abstract: Described is a medicament delivery device comprising a case adapted to hold a container with a medicament and having a needle, a needle sleeve telescopically coupled to the case and having a first extended position relative to the case in which the needle is covered, a retracted position relative to the case in which the needle is exposed, and a second extended position relative to the case in which the needle is covered, a first indicia disposed on the needle sleeve which is visible in the first extended position and the second extended position, and a second indicia disposed on the needle sleeve and not visible in the first extended position and visible the second extended position.

Abstract: An auto-injector for administering a dose of a liquid medicament (M) is present having a tubular chassis telescopable in a tubular case, a carrier subassembly comprising a tubular carrier slidably arranged relative to the chassis inside the case, where the carrier is adapted to contain a syringe with a hollow injection needle. The injector also has a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier. A control spring is arranged around the carrier for translating the carrier in a proximal direction (P) for insertion of the needle through the chassis into an injection site.

Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).